SINOVAC has initiated a phase I/II clinical trial on its bivalent vaccine in China since September 2023. The results from Phase I/II clinical trial demonstrated that the vaccine candidate has ...
Adcendo exercises its option to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need; This col ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback